Thanks Seeker, the due diligence teamwork here has been awesome to be a small part of...and when CEO Rotman starts delivering the entire next sequence of valuation driving catalysts en route we will be getting the last and best laugh for a long long time to come right!
And there's no such thing as martyrs on any stock. There's only bitter babies who either have a personal axe to grind with people or a stock...or bitter ex holders who decided to exit a position then hang around for fear that the position will run without them.
And the sheer amount of silly complaints here over a 10K that reflected phenomenal YOY revenue growth of +1942%, a massive increase in VYST's foundational asset base, and a major reduction in the convertible aged debt that resulted in the complete elimination of ALL toxic noteholders and ALL convertible aged debt is hilarious, especially considering how close we are to the dramatic and explosive increase the Rotmans acquisition will soon be providing and the incredible leverage it will provide!
VYST is following a blue print to growth few OTC Companies have ever successfully executed on, and the only disappointing news in the 10-K was the 1.04B O/S after the over-whelming majority of us longs thought the O/S was only approx. 600M. But the 1.04B O/S includes all the massive dilution from the final toxic noteholder conversions that drove this stock down to .0006 in the 1st 9 calendar days of 2019, and there's been ZERO dilution since, and a simultaneous dramatic increase in the insider ownership position as reflected in the Form 4's, along with a simultaneous dramatic increase in the insider associates ownership position too. So the true free trading effective float in play right now is approx. 400M at the most, and a large percentage of that is locked down by us joe retail investors, and approx. 100M shares are a result of over conversions still under review.
And the best part of the significant collective insider ownership position here is that the insiders can easily get together and agree to retire a large percentage of their position which dramatically reduces the 1.04B O/S if they deem it necessary. And VYST still has their share repurchase program coming and the strong likelihood of a major friendly equity financing ahead, so VYST's still upcoming buyback program along with the approx. 100M over conversion shares could also have a big impact on the eventual O/S reduction if VYST still deems it necessary by the time they're ready to up list onto the NAZ.
But for sure everyone overlooking what this company's biz/growth model consists of, is grossly underestimating what's coming in the form of more accretive asset acquisitions, more accretive company acquisitions, and especially underestimating the BIG name contracts VYST's subsidiary companies are now favorably positioned to start securing after several quarters of extensive R&D and final talks/testing has already occurred.
Their Vytex division alone could become a multi-million dollar rapid revenue driver that absolutely explodes on a Q over Q basis for example, especially now that we know soft launch commercialization endeavors have already been rolled out in Q1 on the Vytex CLOUD bed-in-a-box and associated products in major retailers like Amazon, Bed Bath and Beyond, Sears, Walmart and Wayfair just to name a few, and there's another 40,000 latex products Vytex possesses proprietary competitive advantages with, that could soon be put into major play over the near term horizon too. Let alone all the mainstream multi-media advertising endeavors they may soon ramp up if/when they do in fact take advantage of a major friendly equity financing piece ahead! And that's just on 1 subsidiary, with both RxAir and FEC expected to move into full-fledged commercialization endeavors too. So this incredible growth story hasn't even been remotely written yet, and the final key Rotman's acquisition foundational building block and the leverage it provides is almost in place, then the real journey begins right cheers!
News 
Market Data 
Discover 
